Trillium Asset Management LLC Makes New $3.23 Million Investment in DexCom, Inc. $DXCM

Trillium Asset Management LLC acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 47,881 shares of the medical device company’s stock, valued at approximately $3,225,000.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. Norges Bank acquired a new position in DexCom during the fourth quarter valued at approximately $483,356,000. AQR Capital Management LLC raised its stake in shares of DexCom by 597.8% during the 4th quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock worth $205,932,000 after purchasing an additional 2,658,158 shares in the last quarter. Deutsche Bank AG bought a new stake in shares of DexCom during the 2nd quarter worth approximately $164,035,000. Employees Provident Fund Board acquired a new stake in shares of DexCom in the 4th quarter valued at approximately $145,352,000. Finally, J. Stern & Co. LLP grew its stake in shares of DexCom by 2,114.8% in the fourth quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock valued at $106,323,000 after buying an additional 1,529,641 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other news, insider Kevin R. Sayer sold 26,756 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider owned 328,970 shares in the company, valued at approximately $25,106,990.40. This trade represents a 7.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the sale, the director directly owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. The trade was a 7.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,035 shares of company stock worth $5,446,673 over the last three months. Company insiders own 0.28% of the company’s stock.

DexCom Price Performance

Shares of DXCM opened at $90.22 on Friday. The company’s 50-day moving average is $77.15 and its 200-day moving average is $70.79. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The firm has a market capitalization of $34.05 billion, a PE ratio of 35.66, a PEG ratio of 1.52 and a beta of 1.41. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $91.96.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. DexCom’s revenue was up 13.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.48 EPS. Equities analysts forecast that DexCom, Inc. will post 2.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Canaccord Genuity Group set a $90.00 price target on shares of DexCom and gave the stock a “buy” rating in a research report on Monday, August 3rd. Royal Bank Of Canada lifted their price objective on shares of DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Robert W. Baird set a $105.00 price objective on shares of DexCom in a research note on Friday, July 31st. Bank of America dropped their target price on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, Barclays reiterated an “underweight” rating and issued a $64.00 target price (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.